Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study

被引：0

作者：

Ramalingam, Suresh S. ^{[1
]}

Carlisle, Jennifer W. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

FUTURE ONCOLOGY | 2024年

关键词：

binimetinib; BRAF; encorafenib; non-small cell lung cancer; podcast; CELL LUNG-CANCER; OPEN-LABEL; MUTATIONS; DABRAFENIB; EFFICACY; FEATURES; IMMUNOTHERAPY; MULTICENTER; VEMURAFENIB; INHIBITORS;

D O I：

10.1080/14796694.2024.2391270

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.

引用

页数：6

共 50 条

[1] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
Planchard, David
Besse, Benjamin
Groen, Harry J. M.
Hashemi, Sayed M. S.
Mazieres, Julien
Kim, Tae Min
Quoix, Elisabeth
Souquet, Pierre-Jean
Barlesi, Fabrice
Baik, Christina
Villaruz, Liza C.
Kelly, Ronan J.
Zhang, Shirong
Tan, Monique
Gasal, Eduard
Santarpia, Libero
Johnson, Bruce E.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
[2] Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne S.
Johnson, Melissa Lynne
Gelsomino, Francesco
Esper, Raymond M.
Nadal, Ernest
Offin, Michael
Provencio-Pulla, Mariano
Otterson, Gregory Alan
Dagogo-Jack, Ibiayi
Alcasid, Ann
Usari, Tiziana
Wilner, Keith D.
Pathan, Nuzhat
Johnson, Bruce E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
Grothey, A.
Tabernero, J.
Taieb, J.
Yaeger, R.
Yoshino, T.
Maiello, E.
Fernandez, E. Elez
Casado, A. Ruiz
Ross, P.
Andre, T.
Kato, T.
Ruffinelli, J.
Graham, J.
Van den Eynde, M.
Vera, R.
Jean, B.
Roussel, E. Carriere
Cahuzac, C.
Issiakhem, Z.
Vedovato, J.
Van Cutsem, E.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S242 - S243
[4] A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne
Johnson, Melissa
Gelsomino, Francesco
Esper, Raymond
Nadal, Ernest
Offin, Michael
Provencio, Mariano
Clarke, Jeffrey
Hussein, Maen
Otterson, Gregory A.
Dagogo-Jack, Ibiayi
Goldman, Jonathan W.
Morgensztern, Daniel
Alcasid, Ann
Usari, Tiziana
Wissel, Paul
Wilner, Keith
Pathan, Nuzhat
Tonkovyd, Svitlana
Johnson, Bruce E.
[J]. FUTURE ONCOLOGY, 2024, 20 (16) : 1047 - 1055
[5] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
Takashima, Atsuo
Kotani, Daisuke
Kato, Takeshi
Satoh, Taroh
Masuishi, Toshiki
Komatsu, Yoshito
Shiozawa, Manabu
Esaki, Taito
Izawa, Naoki
Takeuchi, Shinji
Bando, Hideaki
Iwasa, Satoru
Hasegawa, Hiroko
Yamaguchi, Toshifumi
Taniguchi, Hiroya
Yoshino, Takayuki
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[6] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
Shahjehan, F.
Kamatham, S.
Chandrasekharan, C.
Kasi, P. M.
[J]. DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
[7] ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
Van Cutsem, E.
Taieb, J.
Yaeger, R.
Yoshino, T.
Maiello, E.
Elez, E.
Dekervel, J.
Ross, P.
Ruiz Casado, A.
Graham, J.
Kato, T.
Ruffinelli, J.
Andre, T.
Roussel, E. Carriere
Klauck, I.
Groc, M.
Grothey, A.
Vedovato, J.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S222 - S222
[8] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
Kato, T.
Kotani, D.
Takashima, A.
Satoh, T.
Masuishi, T.
Komatsu, Y.
Shiozawa, M.
Esaki, T.
Izawa, N.
Takeuchi, S.
Bando, H.
Iwasa, S.
Hasegawa, H.
Yamaguchi, T.
Taniguchi, H.
Yamada, S.
Yoshino, T.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
[9] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
Aderka, D.
Kopetz, S.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Golden, A.
Edwards, M.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
[10] Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
Augustyn, Kourtney
Joseph, Jocelyn
Patel, Anisha B.
Razmandi, Azadeh
Ali, Amatul Noor
Tawbi, Hussein A.
[J]. MELANOMA RESEARCH, 2023, 33 (05) : 406 - 416

← 1 2 3 4 5 →